- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05072574
Quality of Life, Nutritional Status and Functional Capacity in People With Advanced Chronic Kidney Disease (ERCANUT)
Assessment of Quality of Life, Nutritional Status and Functional Capacity in People With Advanced Chronic Kidney Disease (CKD) After the Implementation of a Nutritional Education Plan and Individualized Dietary Intervention
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Randomized study including two parallel groups: patients from the advanced chronic kidney disease (CKD) consulting room of the Malaga University Regional Hospital and controls. The main objective is to assess the clinical response (quality of life, nutritional status, functional capacity, and disease knowledge) of advanced CKD patients who undergo an individualized dietary intervention and a nutritional education program (group workshops) using motivation coaching techniques, compared to controls who receive general hygiene-nutritional education at every visit.
Both groups will be composed of 54 participants. The control group will be provided general dietary and lifestyle recommendations (standard procedure in the nephrology consulting room), whereas the intervention group will receive treatment and individualized dietary follow-up using coaching techniques, supported by information and communication technologies, and will participate in a nutritional education program composed of four on-line sessions.
Two visits (basal and three months after) will be scheduled during the study to obtain and analyse the data. Moreover, in these visits researchers will collect a blood sample in order to perform an assessment of the metabolism, inflammation, and oxidation, and a stool sample in order to evaluate the gut microbiota.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Málaga, Spain, 29009
- Hospital Regional Universitario de Malaga
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients >18 years old with advanced CKD (GFR <30ml/min) starting follow-up in the advanced CKD consulting room of the Malaga University Regional Hospital and who clearly understand the study and give their informed consent.
Exclusion Criteria:
Patients presenting any of these conditions:
- Active cancer
- Being already participants of another study that may affect the results
- Pregnancy or possible pregnancy
- Informed consent refusal
- Hospital admission during one month previous to the study
- Severe mental disorders (SMD), prolonged mental disorders involving a high level of disability and social dysfunction, which requires attendance by the mental health and social care network
- Alcohol or any other substance abuse that, in the researcher's opinion, may interfere with the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Experimental: nutritional education program
Specific dietary treatment and follow-up using coaching techniques, supported by new technologies, and will attend a nutritional education program
|
Intervention group will receive specific dietary treatment and follow-up using coaching techniques, supported by new technologies, and will attend a nutritional education program
|
|
No Intervention: Control Group
Dietary and general lifestyle recommendations
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Assess the clinical response after the quality of life intervention
Time Frame: From baseline to week 12
|
Kidney Disease and Quality of Life test (KDQOL-36).
The generic component of the KDQOL-36 (items 1-12) is the SF-12, which allows obtaining 2 general scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS).
The specific component of the KDQOL-36 (items 13-36), allows obtaining the scores of the specific subscales for the disease.
|
From baseline to week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in weight
Time Frame: From baseline to week 12
|
Weight in kg
|
From baseline to week 12
|
|
BMI (body mass index) changes
Time Frame: From baseline to week 12
|
Measured by body composition analysis
|
From baseline to week 12
|
|
Change in cholesterol concentration
Time Frame: From baseline to week 12
|
Serum cholesterol in mg/dl
|
From baseline to week 12
|
|
Change in HDL concentration
Time Frame: From baseline to week 12
|
Serum HDL in mg/dl
|
From baseline to week 12
|
|
Change in LDL concentration
Time Frame: From baseline to week 12
|
Serum LDL in mg/dl
|
From baseline to week 12
|
|
Characterize exercise participant behavior
Time Frame: From baseline to week 12
|
International Physical Activity Questionnaire (IPAQ).
The IPAQ consists of 7 questions about the frequency, duration and intensity of activity (moderate and intense) carried out in the last seven days, as well as walking and sitting time in a work day.
It evaluates three characteristics of physics (PA): intensity (mild, moderate or vigorous), frequency (days per week) and duration (time per day).
Weekly activity is recorded in Mets (Metabolic Equivalent of Task or Metabolic Index Units) per minute and week.
|
From baseline to week 12
|
|
Assess the clinical response after intervention in the management of CKD
Time Frame: From baseline to week 12
|
Self-Efficacy for Managing Chronic Disease test. The Self-Efficacy Scale for the Management of Chronic Diseases (SEMCD) is made up of 6 items on an analog scale, ranging from 1 (not at all sure) to 10 (totally safe). The Spanish version (SEMCD-S) consists of 4 items. A higher number means greater self-efficacy. The scale score is the mean of the items. |
From baseline to week 12
|
|
Assess the clinical response after the intervention in knowledge about the disease
Time Frame: From baseline to week 12
|
Kidney Disease Knowledge Survey test.
The Kidney Disease Knowledge Survey (KiKS) instrument consists of 28 items and aims to assess specific knowledge about chronic kidney disease in non-dialysis patients.
One point is considered for each correct answer and zero for the incorrect one.
The total score is calculated by adding all the correct points and divided by 28, obtaining a value from 0 to 1, with 1 being the highest level of knowledge.
|
From baseline to week 12
|
|
Change in fat free body mass
Time Frame: From baseline to week 12
|
Fat free body mass in kg assessed by bioelectrical impedance analysis
|
From baseline to week 12
|
|
Change in upper arm circumference
Time Frame: From baseline to week 12
|
circumference in cm
|
From baseline to week 12
|
|
Change in arm muscle circumference
Time Frame: From baseline to week 12
|
circumference in cm
|
From baseline to week 12
|
|
waist circumference
Time Frame: From baseline to week 12
|
circumference in cm
|
From baseline to week 12
|
|
Change in serum potassium concentration (assess kidney function)
Time Frame: From baseline to week 12
|
serum potassium in mEq/l
|
From baseline to week 12
|
|
Change in serum phosphorus concentration (assess kidney function)
Time Frame: From baseline to week 12
|
serum phosphorus mg/dl
|
From baseline to week 12
|
|
Change in glomerular filtration (assess kidney function)
Time Frame: From baseline to week 12
|
Calculated with the formula of CKD-EPI and MDRD and measured in ml/ min/ 1.73 m2
|
From baseline to week 12
|
|
Change in serum albumin concentration
Time Frame: From baseline to week 12
|
Serum albumin in g/dl
|
From baseline to week 12
|
|
Change in serum prealbumin concentration
Time Frame: From baseline to week 12
|
Serum prealbumin in mg/dl
|
From baseline to week 12
|
|
Change in TG concentration
Time Frame: From baseline to week 12
|
Serum TG in mg/dl
|
From baseline to week 12
|
|
Changes in plasma levels of high sensitivity C reactive protein (hs-CRP)
Time Frame: From baseline to week 12
|
Plasma levels of high sensitivity C reactive protein (hs-CRP) in mg/dl
|
From baseline to week 12
|
|
Changes in blood cells
Time Frame: From baseline to week 12
|
Blood count
|
From baseline to week 12
|
|
Change in iron concentration
Time Frame: From baseline to week 12
|
Serum iron in μg/dl
|
From baseline to week 12
|
|
Change in ferritin concentration
Time Frame: From baseline to week 12
|
Serum ferritin in ng/ml
|
From baseline to week 12
|
|
Change in uric acid concentration
Time Frame: From baseline to week 12
|
Serum uric acid in mg/dl
|
From baseline to week 12
|
|
Change in urea concentration
Time Frame: From baseline to week 12
|
Serum uric acid in mg/dl
|
From baseline to week 12
|
|
Change in magnesium concentration
Time Frame: From baseline to week 12
|
Serum magnesium in mg/dl
|
From baseline to week 12
|
|
Change in calcium concentration
Time Frame: From baseline to week 12
|
Serum calcium in mg/dl
|
From baseline to week 12
|
|
Change in intact parathyroid hormone (PTHi) concentration
Time Frame: From baseline to week 12
|
Serum intact parathyroid hormone (PTHi) in pg/ml
|
From baseline to week 12
|
|
Changes in vitamin D
Time Frame: From baseline to week 12
|
Serum vitamin D in ng/ml
|
From baseline to week 12
|
|
Changes in metabolic control
Time Frame: From baseline to week 12
|
Measured as HbA1c (glycated hemoglobin)
|
From baseline to week 12
|
|
Assess changes in the degree of depression and / or anxiety
Time Frame: From baseline to week 12
|
HADS depression and anxiety symptoms screening test.
It is a self-administered scale with 14 items divided into 2 subscales (anxiety and depression) whose maximum score is 21 points for each of them.
Based on the score obtained, the patients can be classified as normal (<7), doubtful (between 8 and 10) and potential clinical case (≥ 11).
The score is referred to the last week.
|
From baseline to week 12
|
|
Assess the clinical response after the intervention on functional capacity
Time Frame: From baseline to week 12
|
Scale of autonomy for activities of daily life "Barthel test".
This test measures the capacity of the person to carry out ten basic activities of daily life, obtaining a quantitative estimate of the degree of dependence of the subject.
The range of possible IB values is between 0 and 100, with 5-point intervals for the original version.
The closer a subject's score is to 0, the more dependency they have; the closer to 100 the more independence.
|
From baseline to week 12
|
|
Assess on functional capacity
Time Frame: From baseline to week 12
|
Physical activity test "Short Physical Performance Battery" SPPB.
This in turn includes 3 tests: balance, gait speed and getting up and sitting in a chair 5 times.
Each test is scored from 0 (worst performance) to 4 (best performance): for the balance test according to a hierarchical combination of performance in the 3 component subtests and for the other 2 tests a score of 0 is assigned to those who do not complete or they attempt the task and scores from 1 to 4 based on the time spent.
In addition, a total score for the entire battery is obtained, which is the sum of the 3 tests and ranges from 0 to 12.
|
From baseline to week 12
|
|
Changes on functional capacity: International Physical Activity Questionnaire (IPAQ)
Time Frame: From baseline to week 12
|
The International Physical Activity Questionnaire (IPAQ) will be used to evaluate the current physical activity level of the participants.
The survey consists of 27 questions and 5 parts.
|
From baseline to week 12
|
|
Change from Handgrip Strength
Time Frame: From baseline to week 12
|
Strength will be recorded by Jamar Hydraulic Hand Dynamometer (Kg)
|
From baseline to week 12
|
|
Change in handgrip strength
Time Frame: From baseline to week 12
|
Handgrip strength in kg, measured by the jamar hydraulic hand dynamometer.
|
From baseline to week 12
|
|
Changes the clinical response after the intervention in blood pressure figures (mmHg).
Time Frame: From baseline to week 12
|
Assess if syastolic and diastolic pressure improves after training and at 6 months of follow-up.
|
From baseline to week 12
|
|
Diet composition: PREDIMED test (Prevention with Mediterranean Diet)
Time Frame: From baseline to week 12
|
Adherence to the Predimed Plus diet pattern 17 (0 - minimum adherence, 17 - maximum adherence)
|
From baseline to week 12
|
Collaborators and Investigators
Investigators
- Principal Investigator: Gabriel Olveira, MD, PhD, Hospital Regional Universitario de Málaga - FIMABIS
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ACKD
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Kidney Diseases
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillCompletedChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Pediatric Kidney Disease | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease, Stage IUnited States
-
Universiti Putra MalaysiaRecruitingChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Requiring Chronic DialysisMalaysia
-
American Academy of Family PhysiciansUniversity of Colorado, Denver; National Institute of Diabetes and Digestive... and other collaboratorsCompletedChronic Kidney Disease | Chronic Renal Insufficiency | Chronic Kidney Insufficiency | Chronic Renal Diseases | Kidney Insufficiency, ChronicUnited States
-
Centre Hospitalier le MansLe Mans UniversiteWithdrawnFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage3 | Chronic Kidney Failure | Chronic Kidney Disease, Stage 4 (Severe)
-
National Taiwan University HospitalCompletedChronic Kidney Disease stage4 | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease Stage 1Taiwan
-
Centre Hospitalier le MansLe Mans UniversiteRecruitingFatigue | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease Stage 3BFrance
-
University of the State of Santa CatarinaUnknownKidney Diseases | Chronic Kidney Diseases | Hemodialysis | Chronic Renal Insufficiency | Renal Dialysis | Chronic Kidney Insufficiency | Chronic Renal DiseasesBrazil
-
Texas A&M UniversityWithdrawnChronic Kidney FailureUnited States
-
Lund UniversityBaxter Healthcare Corporation; Universidad de CórdobaCompletedEnd Stage Kidney Disease | Chronic Kidney Disease Requiring Chronic DialysisArgentina
-
Benha UniversityCompletedChronic Kidney Diseases | Chronic Kidney Disease 5DEgypt
Clinical Trials on Specific dietary treatment and follow-up using coaching techniques
-
Rabin Medical CenterUnknown
-
The Third Xiangya Hospital of Central South UniversityEnrolling by invitation
-
University of California, San FranciscoETR Associates; William and Flora Hewlett FoundationCompletedSexually Transmitted Diseases | Contraceptive BehaviorUnited States
-
National Taiwan University HospitalNot yet recruitingStroke | Atrial Fibrillation | Artificial IntelligenceTaiwan
-
Institut Claudius RegaudCompleted
-
Hospital Universitario 12 de OctubreFundacion Investigacion Biomedica Hospital 12 de Octubre; Consorcio Centro... and other collaboratorsRecruiting
-
University of IcelandMemorial Sloan Kettering Cancer Center; Landspitali University Hospital; deCODE... and other collaboratorsActive, not recruitingMonoclonal Gammopathy of Undetermined SignificanceIceland
-
Universitaire Ziekenhuizen KU LeuvenUniversitair Ziekenhuis Brussel; Kom Op Tegen KankerCompletedGeriatrics | Comprehensive Geriatric AssessmentBelgium
-
Instituto de Cardiologia do Rio Grande do SulCompleted
-
Instituto de Cardiologia do Rio Grande do SulCompleted